Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 119

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 119
---
 Our ability to receive                                                      
 approval and commercialize product candidates outside of the United States; |

| ● | Our ability to establish                                      
 and maintain collaborations, licensing or other arrangements; |

| ● | Our ability and third parties’                     
 abilities to protect intellectual property rights; |

| ● | costs related to and outcomes              
 of potential litigation or other disputes; |

| ● | Our ability to adequately 
 support future growth;    |

| ● | Our ability to attract                                       
 and retain key personnel to manage our business effectively; |

| ● | potential liabilities associated 
 with hazardous materials;        |

| ● | Our ability to maintain          
 adequate insurance policies; and |

| ● | future accounting pronouncements       
 or changes in our accounting policies. |

The cumulative effect of
such factors could result in large fluctuations and unpredictability in quarterly and annual operating results. As a result, comparing
operating results on a period-to-period basis may not be meaningful. Investors should not rely on past results as an indication of future
performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial
analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below
any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors,
the price of our Common Stock could decline substantially. Such a stock price decline could occur even when we have met any previously
publicly stated revenue and/or earnings guidance we may provide.

Anti-takeover provisions under our organizational documents and Delaware law could delay or prevent a change of control which could limit the market price of our Common Stock and may prevent or frustrate attempts by our stockholders to replace or remove our then-current management.

Our Charter and Bylaws,
contain provisions that could delay or prevent a change of control of our board of directors that our stockholders might consider favorable.
Some of these provisions include:

| ● | a board of directors divided                                                                                                      
 into three classes serving staggered three-year terms, such that not all members of the board of directors will be elected at one 
 time;                                                                                                                             |

| ● | a prohibition on stockholder                                                                                           
 action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders; |

| ● | a requirement that special                                                                                                         
 meetings of stockholders be called only by the chairperson of our board of directors, our Chief Executive Officer or by a majority